Literature DB >> 11696792

Fetal intervention for myelomeningocele: effect on postnatal bladder function.

N M Holmes1, H T Nguyen, M R Harrison, D L Farmer, L S Baskin.   

Abstract

PURPOSE: Myelomeningocele is the most common congenital malformation of the central nervous system noted on prenatal ultrasound. Due to its significant postnatal sequelae, treatment in utero could potentially have a profound impact on the newborn. Others have reported fetal surgical techniques for in utero repair of myelomeningocele and its potential benefits on motor and neurological function. We report our urodynamic findings in the newborn after in utero repair of spina bifida in an effort to characterize postnatal bladder function.
MATERIALS AND METHODS: A retrospective review of the fetal surgery database at University of California San Francisco was performed identifying patients with a diagnosis of myelomeningocele. Prenatal surgical repair of myelomeningocele was considered if a normal karyotype was present, no other significant congenital anomalies were evident and gestational age was less than 24 weeks. The spinal defects were in the lumbar or lumbosacral region. All surgery was performed before 24 weeks of gestations.
RESULTS: Fetal surgery to correct myelomeningocele was performed in 6 patients. All patients were born premature at 32 weeks of gestation or less. Videourodynamics performed at age 1 month in 4 patients indicated decreased bladder capacity for weight, increased detrusor storage pressures and significant post-void residual. Hydronephrosis was demonstrated in 4 patients on renal/bladder ultrasound, and moderate vesicoureteral reflux was seen in 3.
CONCLUSIONS: Patients with spinal bifida treated in utero appear to have the same changes in urodynamic parameters and anatomical abnormalities in the urinary tract as other children with spinal defects who have undergone standard postnatal care. In utero treatment of spinal bifida may expose the newborn to the effects of prematurity. The long-term effects on bladder function in the fetus after in utero repair of myelomeningocele remain unknown. A randomized controlled trial is necessary to evaluate long-term bladder function as well as other outcome variables in this experimental approach to patients with myelomeningocele.

Entities:  

Mesh:

Year:  2001        PMID: 11696792     DOI: 10.1016/s0022-5347(05)65596-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Fetal surgery for myelomeningocele.

Authors:  Payam Saadai; Diana L Farmer
Journal:  Clin Perinatol       Date:  2012-05-15       Impact factor: 3.430

2.  Minimally invasive fetoscopic interventions: an overview in 2010.

Authors:  Thomas Kohl
Journal:  Surg Endosc       Date:  2010-03-17       Impact factor: 4.584

Review 3.  In utero intervention for urologic diseases.

Authors:  Douglass B Clayton; John W Brock
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

Review 4.  Current State of Fetal Intervention for Lower Urinary Tract Obstruction.

Authors:  Douglass B Clayton; John W Brock
Journal:  Curr Urol Rep       Date:  2018-02-22       Impact factor: 3.092

5.  Low level myelomeningoceles: do they need prenatal surgery?

Authors:  Pierre-Aurelien Beuriat; Isabelle Poirot; Frederic Hameury; Delphine Demede; Kieron J Sweeney; Alexandru Szathmari; Federico Di Rocco; Carmine Mottolese
Journal:  Childs Nerv Syst       Date:  2019-03-27       Impact factor: 1.475

6.  Fetal spina bifida in a mouse model: loss of neural function in utero.

Authors:  Dorothea Stiefel; Andrew J Copp; Martin Meuli
Journal:  J Neurosurg       Date:  2007-03       Impact factor: 5.115

7.  Bladder Function After Fetal Surgery for Myelomeningocele.

Authors:  John W Brock; Michael C Carr; N Scott Adzick; Pamela K Burrows; John C Thomas; Elizabeth A Thom; Lori J Howell; Jody A Farrell; Mary E Dabrowiak; Diana L Farmer; Earl Y Cheng; Bradley P Kropp; Anthony A Caldamone; Dorothy I Bulas; Susan Tolivaisa; Laurence S Baskin
Journal:  Pediatrics       Date:  2015-10       Impact factor: 7.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.